Kumaraswamy Nanthakumar, MD, FRCPC

Dr. Nanthakumar has been a Cardiologist and Cardiac Electrophysiologist at Toronto General Hospital for over 20 years, where he has served as Director of Heart Rhythm Disorders for a decade. He became a full Professor of Medicine at the University of Toronto in 2014 and is also a Senior Scientist at the Toronto General Hospital Research Institute. He is a dedicated teacher with multiple teaching awards, passionate about training and mentoring future electrophysiologists, locally and internationally, in complex electrophysiological interventions. He holds global acclaim in intracardiac mapping, with DeEP, Omnipolar, and Repolarization mapping among his fields of expertise. He has a Scopus publication record of over 230 original peer-reviewed journal articles. He is also an inventor/innovator at Techna. He has been granted sixteen patents or intellectual property (IP) rights in North America and Europe and is actively engaged in the commercialization of his IP.

He is an alumnus of the medical school at the University of Toronto, class of 1995. He subsequently completed postgraduate training in Internal Medicine and Cardiology at the University of Toronto for an additional 6 years, followed by an additional 3-year sub-specialization in arrhythmias and cardiac electrophysiology at the University of Alabama in Birmingham. There, he studied the mechanisms of cardiac arrhythmias and built expertise in cardiac mapping and ablations. His clinical expertise focuses on devices for heart failure and performing catheter ablation of ventricular tachycardia and supraventricular tachycardia.

The most common causes of sudden cardiac death are ventricular fibrillation (VF) and ventricular tachycardia (VT). Dr. Nanthakumar is focused on mapping and ablation strategies for VT in heart failure. Specifically, his current research is on treating cardiac arrhythmias based on repolarization mapping and novel catheter designs. The objective of Dr. Nanthakumar’s research program for the past two decades was to understand the mechanisms of human VF and VT, as well as the factors that modulate them. Having studied mechanisms of VF and VT for 20 years, his research has shifted towards ventricular arrhythmogenesis in onco-cardiology. He is also a pioneer in research on onco-arrhythmias and cardiac dysfunction due to the cardiotoxicity of chemotherapy medications, such as anthracyclines and Bruton's tyrosine kinase inhibitors. His laboratory is devising new therapies for these emerging clinical issues.

Dr. Nanthakumar's laboratory is also focused on commercialization and working to commercialize intellectual properties on RyR2 modulation and novel cardiac mapping technologies. Other commercialization efforts include the co-development of the mapping methodology of DeEP VT mapping technology with Biosense Webster. His latest focus on mapping research relates to repolarization mapping and electrotomographic mapping for clinical applications. His laboratory was crucially involved in co-developing Omnipolar mapping with Abbott Laboratories.

For a list of Dr. Nanthakumar's publications, please visit PubMed or Scopus.


Active Staff, Toronto General Hospital and Mount Sinai Hospital
Graduate Appointment, Institute of Medical Science
Â